This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2005 Nov 8;65(9):1508-9.

doi: 10.1212/01.wnl.0000183145.91579.74.

Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG

Y Hatanaka¹, S Hemmi, M B Morgan, M L Scheufele, G C Claussen, G I Wolfe, S J Oh

Affiliations

PMID: 16275854
DOI: 10.1212/01.wnl.0000183145.91579.74

Comparative Study

Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG

Y Hatanaka et al. Neurology. 2005.

. 2005 Nov 8;65(9):1508-9.

doi: 10.1212/01.wnl.0000183145.91579.74.

Authors

Y Hatanaka¹, S Hemmi, M B Morgan, M L Scheufele, G C Claussen, G I Wolfe, S J Oh

Affiliation

¹ Department of Neurology, The University of Alabama, Birmingham, AL 35294, USA.

PMID: 16275854
DOI: 10.1212/01.wnl.0000183145.91579.74

No abstract available

PubMed Disclaimer

Similar articles

Anti-musk antibody after thymectomy in a previously seropositive myasthenic child.
Saulat B, Maertens P, Hamilton WJ, Bassam BA. Saulat B, et al. Neurology. 2007 Aug 21;69(8):803-4. doi: 10.1212/01.wnl.0000267694.45244.f4. Neurology. 2007. PMID: 17709714 No abstract available.
Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A, Saruhan-Direskeneli G. Deymeer F, et al. Neurology. 2007 Feb 20;68(8):609-11. doi: 10.1212/01.wnl.0000254620.45529.97. Neurology. 2007. PMID: 17310034
Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients.
Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, Drachman DB. Zhou L, et al. Muscle Nerve. 2004 Jul;30(1):55-60. doi: 10.1002/mus.20069. Muscle Nerve. 2004. PMID: 15221879
Autoimmune myasthenia gravis in childhood.
Andrews PI. Andrews PI. Semin Neurol. 2004 Mar;24(1):101-10. doi: 10.1055/s-2004-829591. Semin Neurol. 2004. PMID: 15229797 Review.
[Immunologic tests: Anti-MuSK antibody].
Ohta M, Ohta K, Shigemoto K. Ohta M, et al. Nihon Rinsho. 2005 Jul;63 Suppl 7:589-91. Nihon Rinsho. 2005. PMID: 16111340 Review. Japanese. No abstract available.

See all similar articles

Cited by

Electrodiagnostic Characteristics Suggestive of Muscle-Specific Kinase Myasthenia Gravis.
Skolka M, Lamb CJ, Rubin DI, Klein CJ, Laughlin RS. Skolka M, et al. Neurol Clin Pract. 2022 Jun;12(3):211-217. doi: 10.1212/CPJ.0000000000001166. Neurol Clin Pract. 2022. PMID: 35747537 Free PMC article.
Outcomes and characteristics of myasthenia gravis: A 10-year retrospective cross-sectional study at King Fahad Medical City.
Ali A, Almalki D, Kotb MA, Alenazi RS. Ali A, et al. Neurosciences (Riyadh). 2022 Oct;27(4):237-243. doi: 10.17712/nsj.2022.4.20220038. Neurosciences (Riyadh). 2022. PMID: 36252965 Free PMC article.
Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies.
Rajakulendran S, Viegas S, Spillane J, Howard RS. Rajakulendran S, et al. J Neurol. 2012 Dec;259(12):2736-9. doi: 10.1007/s00415-012-6661-9. Epub 2012 Sep 7. J Neurol. 2012. PMID: 22955633 Review. No abstract available.
Treatment of Myasthenia Gravis.
Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Farmakidis C, et al. Neurol Clin. 2018 May;36(2):311-337. doi: 10.1016/j.ncl.2018.01.011. Neurol Clin. 2018. PMID: 29655452 Free PMC article. Review.
Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.
Koneczny I, Herbst R. Koneczny I, et al. Cells. 2019 Jul 2;8(7):671. doi: 10.3390/cells8070671. Cells. 2019. PMID: 31269763 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information